Ryan Allway June 27th, 2022 Psychedelics, Top News — Marks the first novel psilocybin analog to enter clinical development —— Patient recruitment to commence immediately —— Pharmacokinetic and safety data readout expected in Q4 2022 — TORONTO, June 27, 2022–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (Cybin or the Company), a biopharmaceutical company... Read more
Tryp Therapeutics Appoints New Chief Operating Officer
June 23, 2022
Sid Taubenfeld with Extensive Experience in the Financial Markets and as a Biotech Executive Joins Tryp as Company Prepares to Expand Patient Access to Psilocybin-Based Treatments San Diego, California — (June 23, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused... Read more
Ryan Allway June 14th, 2022 Psychedelics, Top News Toronto, Ontario–(Newsfile Corp. – June 14, 2022) – Silo Wellness Inc. (CSE: SILO) (OTCQB: SILFF) (FSE: 3K70) (“Silo Wellness” or the “Company“), a leading global psychedelics company, announces a request for expressions of interests from Oregon property owners who may be... Read more
Initial data readout supports the potential effectiveness of psilocybin and psilocybin-related compounds for the treatment of Binge Eating Disorder San Diego, California — (June 9, 2022) – Tryp Therapeutics, Inc. (CSE: TRYP) (OTCQB: TRYPF) (“Tryp” or the “Company”), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet... Read more
Ryan Allway May 27th, 2022 Psychedelics, Top News Halucenex to receive recently harvested first batch of psilocybe cubensis May 27, 2022 VANCOUVER, BC — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian company producing natural, scalable, and accessible mushroom formulations for transformational human... Read more
Ryan Allway May 12th, 2022 Psychedelics, Top News — Review of Phase I ready BMB-101 and upcoming milestones — — Webcast to be held on May 19, 2022, 4:00pm ET — VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”)... Read more
Ryan Allway May 3rd, 2022 News, Top News Conference Call on Tuesday, May 3, 2022 at 2:00pm EST LOS ANGELES, May 03, 2022 (GLOBE NEWSWIRE) — Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) (FRA: 97X) (“Irwin” or the “Company”) today announced the Company will file its results for the fiscal fourth... Read more
Ryan Allway March 2nd, 2022 Psychedelics, Top Story OXFORD, Ohio and COCONUT CREEK, Fla., March 2, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of... Read more
Optimi Health Approved to Supply Psilocybin Under Health Canada’s Special Access Program
February 16, 2022
VANCOUVER, BC (GLOBE NEWSWIRE – February 16, 2022) — Optimi Health Corp. (CSE: OPTI) (OTCQB: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), developers of a vertically integrated mushroom brand targeting functional and novel psychedelic compounds for the health and wellness sector, is pleased to report that Health Canada has added the... Read more
Filament Health Announces Health Canada Approval For Phase II Trial Administering New Psilocybin Microdose Formulation
January 4, 2022
Ryan Allway January 4th, 2022 Psychedelics The clinical trial at the University of Toronto will study low doses of psilocybin in healthy subjectswith persistent depressive disorder VANCOUVER, BC, Jan. 4, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced... Read more
